Abstract
Background Congenital toxoplasmosis is a treatable, preventable disease, but untreated causes death, prematurity, loss of sight, cognition and motor function, and substantial costs worldwide.
Methods/Findings In our ongoing USA feasibility/efficacy clinical trial, data collated with other ongoing and earlier published results proved high performance of an Immunochromatographic-test(ICT) that enables accurate, rapid diagnosis/treatment, establishing new paradigms for care. Overall results from patient blood and/or serum samples tested with ICT compared with gold-standard-predicate-test results found ICT performance for 4606 sera/1876 blood, 99.3%/97.5% sensitive and 98.9%/99.7% specific. However, in the clinical trial the FDA-cleared-predicate test initially caused practical, costly problems due to false-positive-IgM results. For 58 persons, 3/43 seronegative and 2/15 chronically infected persons had false positive IgM predicate tests. This caused substantial anxiety, concerns, and required costly, delayed confirmation in reference centers. Absence of false positive ICT results contributes to solutions: Lyon and Paris France and USA Reference laboratories frequently receive sera with erroneously positive local laboratory IgM results impeding patient care. Therefore, thirty-two such sera referred to Lyon’s Reference laboratory were ICT-tested. We collated these with other earlier/ongoing results: 132 of 137 USA or French persons had false positive local laboratory IgM results identified correctly as negative by ICT. Five false positive ICT results in Tunisia and Marseille, France, emphasize need to confirm positive ICT results with Sabin-Feldman-Dye-test or western blot. Separate studies demonstrated high performance in detecting acute infections, meeting FDA, CLIA, WHO ASSURED, CEMark criteria and patient and physician satisfaction with monthly-gestational-ICT-screening.
Conclusions/Significance This novel paradigm using ICT identifies likely false positives or raises suspicion that a result is truly positive, rapidly needing prompt follow up and treatment. Thus, ICT enables well-accepted gestational screening programs that facilitate rapid treatment saving lives, sight, cognition and motor function. This reduces anxiety, delays, work, and cost at point-of-care and clinical laboratories.
Author’s Summary Toxoplasmosis is a major health burden for developed and developing countries, causing damage to eyes and brain, loss of life and substantial societal costs. Prompt diagnosis in gestational screening programs enables treatment, thereby relieving suffering, and leading to > 14-fold cost savings for care. Herein, we demonstrate that using an ICT that meets WHO ASSURED-criteria identifying persons with/without antibody to Toxoplasma gondii in sera and whole blood with high sensitivity and specificity, is feasible to use in USA clinical practice. We find this new approach can help to obviate the problem of detection of false positive anti-T.gondii IgM results for those without IgG antibodies to T.gondii when this occurs in present, standard of care, predicate USA FDA cleared available assays. Thus, this accurate test facilitates gestational screening programs and a global initiative to diagnose and thereby prevent and treat T.gondii infection. This minimizes likelihood of false positives (IgG and/or IgM) while maintaining maximum sensitivity. When isolated IgM antibodies are detected, it is necessary to confirm and when indicated continue follow up testing in ∼2 weeks to establish seroconversion. Presence of a positive ICT makes it likely that IgM is truly positive and a negative ICT makes it likely that IgM will be a false positive without infection. These results create a new, enthusiastically-accepted, precise paradigm for rapid diagnosis and validation of results with a second-line test. This helps eliminate alarm and anxiety about false-positive results, while expediting needed treatment for true positive results and providing back up distinguishing false positive tests.
Competing Interest Statement
Funding, Acknowledgements, Disclosures and Insuring Objectivity in Results LDBio Diagnostics provided the ICT and Western Blots used in the studies. ANNAR Labs (Colombia) donated the AdBio kits. For the predicate test, costs for the comparison test for 58 persons for the feasibility, clinical trial the cost of performing the Biorad IgG and IgM tests was provided by the Susan and Richard family Kiphardt Seed Fund and The Thrasher Children?s Charity. At LDBio Diagnostics, Denis Limonne Pharm D. is the scientist and CEO share holder and Raphael Piarroux PharmD, PhD was the R&D Director Scientist until January 13, 2023. A patent application was submitted by D. Limonne with the scientists at the University of Chicago and in France in August 2018. This application is pending review in the United States in accordance with US Bayh Dole laws. This is for the development of the whole blood point of care test and the practical clinical utility of the ICT to guide treatment for gestational infection to prevent congenital toxoplasmosis. This is to insure its continued high-quality performance and reproducibility of the results described herein. It is pending in review at the US patent office. In this collaborative work, the scientists D. Limonne and R. Piarroux (DL.RP) at LDBio provided insights and knowledge from their earlier work in creating the ICT, and collaboratively with RMc discussed FDA and CLIA requirements with RMc and the FDA during an IDE and ?presubQ? phase of this study. In this phase, the FDA Program provided guidance for this academic /Biotek collaboration to prepare materials to allow FDA review for dual 510K clearance and CLIA waiver for use of the ICT in the USA. RP of LDBio performed the analysis of the French Blood bank serum to establish that the correct dilution required by CLIA instructions was 1:89. DL and RP designed the instruction sheet with input from FDA, CLIA, and RMc to be tested in the QI at limits of detection study?. This was perfected in the presubQ process with advice from the FDA and CLIA as the FDA indicated that a 510K clearance and dual CLIA waiver might be the appropriate application mechanism. The scientists at LDBio did not interfere with the performing of the tests, the recording, interpretation of the results nor the reported conclusions of any work at any academic site. All these studies were performed independently in the academic centers. There was no payment to the scientists. At Hopital Bichat, Paris and in Morocco studies were/are being reported separately. LDBio did provide resources to support operating expenses and reagents, but not in the USA or Colombia. RP and DL participated in editing initial and final drafts of the manuscript. The ICT tests of the Cincinnati samples and three western blots for Chicago samples were performed at LDBio. We gratefully acknowledge all participants in this work and those at the FDA who worked with us in the ?Pre-Sub Q process? recognizing the substantial potential humanitarian benefit of the work toward obtaining FDA clearance and CLIA waiver that could allow this work and test to be used to help people and prevent suffering and loss of life, sight, cognition, and motor function, while saving costs for health care. Additional thanks for funding from the Medical Student Award, the National Institute of Diabetes and Digestive and Kidney Diseases for their Grant #T35DK062719-30, the National Institutes of Health for their Division of Microbiology and Infectious Diseases Grant to RMc #R01 AI2753,RO1 16945, AI08749-01A1 BIOL-3, U01 AI77887, U01 AI082180, TMP R01-AI071319, the Thrasher Children?s Charity Research Fund for their E.W. ?Al? Thrasher Award, the Kiphart Global-Local Health Seed Fund Award (to RMc), University of Chicago. We are grateful to Taking out Toxo, Network for Good, Toxoplasmosis Research Institute, The Cornwell Mann Family Foundation, The Rodriguez family, The Samuel family and Running for Fin, the Morel, Rooney, Mussalami, Kapnick, Taub, Engel, Harris, Drago,Longfellow/Van Dusen families, and the study participants. We thank testers E.McLeod, C.Weber, F.Goldenberg, C. Guinnette, R. Tennant, Z. Williams, H.Taylor, A. Beem, and S.Syed and photographers E.McLeod and K El Bissati for their reading and photography in the limit of detection, QI study. We thank all the participants in these studies of the ICT and those in the IRB office, members on the IRB, Office of Clinical Research, at the FDA and CLIA for their guidance and A. Ponsler at the Thrasher Foundation for emphasizing the importance of these studies on reviewing the initial data at a site visit at Stanford University and the Remington Serology laboratory with RMc.
Clinical Trial
Clinical Trials.gov number NCT04474132
Funding Statement
Funding, Acknowledgements, Disclosures and Insuring Objectivity in Results LDBio Diagnostics provided the ICT and Western Blots used in the studies. ANNAR Labs (Colombia) donated the AdBio kits. For the predicate test, costs for the comparison test for 58 persons for the feasibility, clinical trial the cost of performing the Biorad IgG and IgM tests was provided by the Susan and Richard family Kiphardt Seed Fund and The Thrasher Children’s Charity. At LDBio Diagnostics, Denis Limonne Pharm D. is the scientist and CEO share holder and Raphael Piarroux PharmD, PhD was the R&D Director Scientist until January 13, 2023. A patent application was submitted by D. Limonne with the scientists at the University of Chicago and in France in August 2018. This application is pending review in the United States in accordance with US Bayh Dole laws. This is for the development of the whole blood point of care test and the practical clinical utility of the ICT to guide treatment for gestational infection to prevent congenital toxoplasmosis. This is to insure its continued high-quality performance and reproducibility of the results described herein. It is pending in review at the US patent office. In this collaborative work, the scientists D. Limonne and R. Piarroux (DL.RP) at LDBio provided insights and knowledge from their earlier work in creating the ICT, and collaboratively with RMc discussed FDA and CLIA requirements with RMc and the FDA during an IDE and “presubQ” phase of this study. In this phase, the FDA Program provided guidance for this academic /Biotek collaboration to prepare materials to allow FDA review for dual 510K clearance and CLIA waiver for use of the ICT in the USA. RP of LDBio performed the analysis of the French Blood bank serum to establish that the correct dilution required by CLIA instructions was 1:89. DL and RP designed the instruction sheet with input from FDA, CLIA, and RMc to be tested in the “QI at limits of detection study”. This was perfected in the “presubQ” process with advice from the FDA and CLIA as the FDA indicated that a 510K clearance and dual CLIA waiver might be the appropriate application mechanism. The scientists at LDBio did not interfere with the performing of the tests, the recording, interpretation of the results nor the reported conclusions of any work at any academic site. All these studies were performed independently in the academic centers. There was no payment to the scientists. At Hôpital Bichat, Paris and in Morocco studies were/are being reported separately. LDBio did provide resources to support operating expenses and reagents, but not in the USA or Colombia. RP and DL participated in editing initial and final drafts of the manuscript. The ICT tests of the Cincinnati samples and three western blots for Chicago samples were performed at LDBio. We gratefully acknowledge all participants in this work and those at the FDA who worked with us in the “Pre-Sub Q process” recognizing the substantial potential humanitarian benefit of the work toward obtaining FDA clearance and CLIA waiver that could allow this work and test to be used to help people and prevent suffering and loss of life, sight, cognition, and motor function, while saving costs for health care. Additional thanks for funding from the Medical Student Award, the National Institute of Diabetes and Digestive and Kidney Diseases for their Grant #T35DK062719-30, the National Institutes of Health for their Division of Microbiology and Infectious Diseases Grant to RMc #R01 AI2753,RO1 16945, AI08749-01A1 BIOL-3, U01 AI77887, U01 AI082180, TMP R01-AI071319, the Thrasher Children’s Charity Research Fund for their E.W. “Al” Thrasher Award, the Kiphart Global-Local Health Seed Fund Award (to RMc), University of Chicago. We are grateful to Taking out Toxo, Network for Good, Toxoplasmosis Research Institute, The Cornwell Mann Family Foundation, The Rodriguez family, The Samuel family and Running for Fin, the Morel, Rooney, Mussalami, Kapnick, Taub, Engel, Harris, Drago,Longfellow/Van Dusen families, and the study participants. We thank testers E.McLeod, C.Weber, F.Goldenberg, C. Guinnette, R. Tennant, Z. Williams, H.Taylor, A. Beem, and S.Syed and photographers E.McLeod and K El Bissati for their reading and photography in the limit of detection, QI study. We thank all the participants in these studies of the ICT and those in the IRB office, members on the IRB, Office of Clinical Research, at the FDA and CLIA for their guidance and A. Ponsler at the Thrasher Foundation for emphasizing the importance of these studies on reviewing the initial data at a site visit at Stanford University and the Remington Serology laboratory with RMc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Chicago Institutional Review Board (IRB)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
A supplement is added
Data Availability
All data are included in the manuscript and its supplement.
